Marker Therapeutics reports Q3 2024 net loss of $2.3M; receives $4M NIH grants

Marker Therapeutics, Inc.

2024-Q3 EPS reported -$0.77 revenue$4,339,317

Cash and cash equivalents of $9.0M as of Sept 30, 2024; expects to fund operations into October 2025.
Net loss from continuing operations improved to $2.3M (Q3 2024) from $3.0M (Q3 2023).
R&D expenses rose to $3.5M (Q3 2024) vs $2.0M (Q3 2023) due to increased clinical trial activity.
Received two $2M SBIR grants from NIH ($4M total) to support MT-601 trials in lymphoma and pancreatic cancer.
Phase 1 APOLLO study of MT-601 in lymphoma continues enrolling; expects preliminary data by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.